Chemistry:SPV-400

From HandWiki

SPV-400 is a tropomyosin receptor kinase B (TrkB) agonist which is under development for the treatment of neurological disorders.[1][2][3] It is taken parenterally.[1] The preclinical pharmacokinetics of SPV-400 have been studied and described.[1][3] The drug is under development by Spave Science.[1][2] As of August 2025, it is in the preclinical research stage of development for neurological disorders.[1][2] The chemical structure of SPV-400 does not yet appear to have been disclosed.[1]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 "SPV 400". 1 August 2025. https://adisinsight.springer.com/drugs/800083617. 
  2. ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on SPV-400 with Synapse". 11 March 2026. https://synapse.patsnap.com/drug/b81ee10c7d6b4791a928d06ee1081b2d. 
  3. ↑ 3.0 3.1 "Absorption, Distribution, Metabolism, And Excretion (ADME) And Pharmacokinetic (PK) Properties of SPV-400, a Novel Tropomyosin Kinase Receptor B (TrkB) Activator (P9-2.002)". Neurology 104 (7_Supplement_1). 8 April 2025. doi:10.1212/WNL.0000000000210660. ISSN 0028-3878. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:SPV-400&oldid=4583645"